- Home
- MRUS
MRUS
Merus N.V.
as 07-26-2024 4:00pm EST
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
| Founded: | 2003 | Country: | Netherlands |
| Employees: | N/A | City: | 3584 CM UTRECHT |
| Market Cap: | 3.8B | IPO Year: | 2016 |
| Target Price: | $76.00 | AVG Volume (30 days): | 762.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.81 - $61.61 | Next Earning Date: | 08-05-2024 |
| Revenue: | $38,337,000 | Revenue Growth: | -11.73% |
| Revenue Growth (this year): | -15.13% | Revenue Growth (next year): | 59.69% |
Stock Insider Trading Activity of Merus N.V. (MRUS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Silverman Peter B. | MRUS | COO & GC | Jun 27 '24 | Sell | $60.00 | 10,000 | $600,000.00 | 0 | SEC Form 4 |
| Silverman Peter B. | MRUS | COO & GC | Jun 17 '24 | Sell | $56.52 | 62,000 | $3,504,178.00 | 0 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Jun 10 '24 | Sell | $57.84 | 7,300 | $422,232.00 | 7,002 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Jun 10 '24 | Sell | $53.22 | 1,000 | $53,224.00 | 7,002 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Jun 4 '24 | Sell | $53.12 | 1,000 | $53,124.00 | 7,002 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Jun 4 '24 | Sell | $52.85 | 5,000 | $264,230.00 | 7,002 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Dec 19 '23 | Sell | $26.68 | 115 | $3,068.20 | 7,002 | SEC Form 4 |
| Silverman Peter B. | MRUS | COO & GC | Dec 15 '23 | Sell | $25.00 | 22,386 | $559,650.00 | 0 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Dec 8 '23 | Sell | $24.44 | 250 | $6,110.00 | 7,117 | SEC Form 4 |
| Shuman Harry | MRUS | VP Controller, PAO | Dec 1 '23 | Sell | $24.58 | 575 | $14,133.50 | 7,367 | SEC Form 4 |
Latest Merus N.V. News
MRUS Breaking Stock News: Dive into MRUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Simply Wall St.
14 days ago
Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%
MT Newswires
18 days ago
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate
GlobeNewswire
19 days ago
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
MT Newswires
25 days ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
25 days ago
Merus Names New Chief Medical Officer
GlobeNewswire
a month ago
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
MT Newswires
a month ago
Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating
Compare MRUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRUS Merus N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.